Brookstone Capital Management’s TG Therapeutics TGTX Stock Holding History

Brookstone Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$963K	Hold	17,521	–	–	0.01%	708
2026 Q1	$582K	Hold	17,521	–	–	0.01%	822
2025 Q4	$522K	Hold	17,521	–	–	0.01%	837
2025 Q3	$633K	Hold	17,521	–	–	0.01%	750
2025 Q2	$631K	Sell	17,521 -87	-0.5%	-$3.24K	0.01%	691
2025 Q1	$694K	Buy	17,608 +87	+0.5%	+$2.93K	0.01%	640
2024 Q4	$527K	Buy	17,521 +624	+4%	+$17.9K	0.01%	680
2024 Q3	$395K	Hold	16,897	–	–	0.01%	753
2024 Q2	$373K	Buy	16,897 +30	+0.2%	+$479	0.01%	729
2024 Q1	$257K	Hold	16,867	–	–	﹤0.01%	807
2023 Q4	$288K	Sell	16,867 -688	-4%	-$8K	0.01%	729
2023 Q3	$117K	Buy	17,555 +436	+3%	+$6.08K	﹤0.01%	799
2023 Q2	$427K	Hold	17,119	–	–	0.01%	617
2023 Q1	$352K	Buy	17,119 +2,919	+21%	+$44.3K	0.01%	661
2022 Q4	$153K	Buy	14,200 +2,475	+21%	+$18K	﹤0.01%	789
2022 Q3	$67K	Buy	+11,725	New	+$76.9K	﹤0.01%	763

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Brookstone Capital Management's TGTX Position: Q2 2026 in Review

Brookstone Capital Management held its TG Therapeutics (TGTX) position steady in Q2 2026 at 17,521 shares worth $963K. The position accounts for 0.01% of the portfolio, ranked #708.

Brookstone Capital Management first reported a position in TGTX in Q3 2022 and has held it in 16 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Brookstone Capital Management held 17,521 shares of TG Therapeutics worth $963K as of Q2 2026.
Brookstone Capital Management left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up 0.01% of Brookstone Capital Management's portfolio in Q2 2026, its #708 holding.
Brookstone Capital Management first reported a position in TG Therapeutics in Q3 2022 and has held it in 16 quarters since.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.